1Martin GDA,Narvaez J,Marti A. Synthesis and bioconver-sions offormestane[J]. JNat Prod,2013,76(10) : 1 966.
2Brodie AM, Garrett WM, Hendrickson JR, et al. Inactiva-tion of aromatase activity in placenta and ovarian microsomes by 4-hydroxyandrostene-3,17-dione and 4-acetoxy-androstene- 3,17-dione and sustained effects in vivo[J].1981,38(6) :693.
3Wing LY,Garrett WM,Brodie AM. Effect of AromataseInhibitors,Aminoglutethimide, and 4-OHA on Cyclic Ratsand Rats with 7,12-Dimethylbenz (a) anthracene-inducedMammary Tumors[J]. Cancer Res, 1985,45(6) :2 425.
4Dowsett M, Goss PE, Powles Thet al. Use of the aroma-tase inhibitors 4-hydroxyandrostenedione in postmeno-pausal breast cancer: optimization of therapeutic dose androute [J]. Cancer Res, 1987,47(7) : 1 957.
5Brodie AM,Garrett WM,Hendrickson JR,et al. Effects ofaromatase inhibitor 4-hydroxyandrostenedione and othercompounds in the 7,12-dimethylbenz (a) anthracene-in-duced breast carcinoma modelfj]. Cancer Res, 1982, 42(8):3 360.
6Chander SK,Lansdown AG, Luqmani YA . Effectivenessof combined limonene and 4-hydroxyandrostenedione inthe treatment of NMU-induced rat mammary tumors[J].Brit J Cancer, 1994,69(5) :879.
7Dowsett M, Cunningham DC, Stein RC.Dose-related en-docrine effects and pharmacokinetics of oral and intramus-cular 4-hydroxyandrostenedione in postmenopausal breastcancer patients[J]. Cancer Res,1989,49(5) : 1 306.
8Cavaliere C, Corvigno S, Galgani Mtet al. Combined in-hibitory effect of formestane and herceptin on a subpopu-lation of CD44+/CD24 low breast cancer cells[J]. Cancer5c/,2010,101(7):1 661.
9Low BS, Choi SB, Abdul WH, et ah Eurycomanone, themajor quassinoid in Eurycoma longifolia root extract in-creases spermatogenesis by inhibiting the activity of phos-phodiesterase and aromatase in steroidogenesis[J]. J Eth-nopharmacol,2013,149(1) :201.
10Braun DP, Crist KA, Shaheen F,et al. Aromatase inhibi-tors increase the sensitivity of human tumor cells to mono-cyte-mediated, antibody-dependent cellular cytotoxicity[J].^w 2005,190(4),570.
